FDA Is Set Decide the Fate of AstraZeneca’s Heart Drug Brilinta
by Melly Alazraki on Dec.15, 2010, under Towing
More than a year after AstraZeneca filed for approval, the FDA will make its decision on Thursday. A large study showed the blood thinner worked better than Plavix for treating acute coronary syndrome — but approval isn’t a sure thing, due in part to some oddities in the study’s results.
Continue reading FDA Is Set Decide the Fate of AstraZeneca’s Heart Drug Brilinta
FDA Is Set Decide the Fate of AstraZeneca’s Heart Drug Brilinta originally appeared on DailyFinance on Wed, 15 Dec 2010 09:35:00.
Filed Under: Company News, Health Care, Bristol-Myers Squibb, Sanofi Aventis, Eli Lilly, Astrazeneca, Stocks in the News



